Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta‐analysis

Siller‐Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, 148, 10.1016/j.ahj.2008.09.017 Siller‐Matula, 2008, Calcium‐channel blockers reduce the antiplatelet effect of clopidogrel, J Am Coll Cardiol, 52, 1557, 10.1016/j.jacc.2008.07.055 Siller‐Matula, 2010, Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay, J Thromb Haemost, 8, 351, 10.1111/j.1538-7836.2009.03699.x Bhatt, 2008, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, J Am Coll Cardiol, 52, 1502, 10.1016/j.jacc.2008.08.002 Siller‐Matula, 2009, Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease, Br J Pharmacol, 159, 502, 10.1111/j.1476-5381.2009.00555.x Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double‐blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Sibbing, 2009, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel, Thromb Haemost, 101, 714, 10.1160/TH08-12-0808 Cuisset, 2009, Comparison of omeprazole and pantoprazole influence on a high 150‐mg clopidogrel maintenance dose, J Am Coll Cardiol, 54, 1149, 10.1016/j.jacc.2009.05.050 Small, 2008, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel, J Clin Pharmacol, 48, 475, 10.1177/0091270008315310 Wiviott, 2007, Circulation, 116, 2923, 10.1161/CIRCULATIONAHA.107.740324 O’Donoghue, 2009, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton‐pump inhibitor: an analysis of two randomised trials, Lancet, 374, 989, 10.1016/S0140-6736(09)61525-7 Juurlink, 2009, A population‐based study of the drug interaction between proton pump inhibitors and clopidogrel, CMAJ, 180, 713, 10.1503/cmaj.082001 Stanek EJ, Aubert R, Flockhart D, Kreutz RP, Yao J, Breall J, Desta Z, Skaar T, Frueh F, Teagarden J, Epstein R. A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study. presented at SCAI, Las Vegas 2009:Abstract O–11. Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 301, 937, 10.1001/jama.2009.261 Sarafoff, 2009, Higher stent thrombosis rate after coronary stenting in patients on dual antiplatelet treatment and concomitant treatment with proton pump inhibitors, Eur Heart J, 30, P150 Banerjee, 2009, Proton pump inhibitors increase the risk of major adverse cardiovascular events in post‐PCI patients who are on clopidogrel, Eur Heart J, 30, P92 Pezalla, 2008, Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors, J Am Coll Cardiol, 52, 1038, 10.1016/j.jacc.2008.05.053 Jarai, 2009, Effects of proton‐pump inhibitors on outcome of patients discharged on dual‐antiplatelet therapy after percutaneous coronary intervention and stent implantation, Eur Heart J Ramirez JF, Selzer F, Chakaprani R, Anderson WD, Lee JS, Smith C, Mulukutla RS, Kip KE, Kelsey SF, Marroquin OC. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: The NHLBI Dynamic Registry. American College of Cardiology Session/i2 Summit 2009; A27: 2903–7. Zairis, 2008, The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting, Eur Heart J, 29, P134 Gaspar, 2009, Proton pump inhibitors in patients treated with aspirin and clopidogrel, Eur Heart J, 30 Simon, 2009, Proton Pump inhibitors and clopidogrel response on cardiovascular major events in patients after acute myocardial infarction. Data from the FAST‐MI registry of the french society of cardiology, Eur Heart J, 30, P2121 Bhatt DL. COGENT: A Prospective, Randomized,Placebo‐Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel. presented at TCT 2009 San Francisco 2009:http://www.tctmd.com/show.aspx?id=86168; Accessed 8 October 2009. Dunn, 2008, Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial, Circulation, 118 Biondi‐Zoccai, 2006, Compliance with QUOROM and quality of reporting of overlapping meta‐analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study, BMJ, 332, 202, 10.1136/bmj.38693.516782.7C Wells, 2001, Minimal clinically important differences: review of methods, J Rheumatol, 28, 406 Rucker, 2008, Undue reliance on I(2) in assessing heterogeneity may mislead, BMC Med Res Methodol, 8, 79, 10.1186/1471-2288-8-79 Zairis, 2010, The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting, Can J Cardiol, 26, e54, 10.1016/S0828-282X(10)70008-8 Gupta, 2010, Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention, Dig Dis Sci, 55, 1964, 10.1007/s10620-009-0960-8 Rassen, 2009, Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome, Circulation, 120, 2322, 10.1161/CIRCULATIONAHA.109.873497 Evanchan, 2010, Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction, Clin Cardiol, 33, 168, 10.1002/clc.20721 Ray, 2010, Outcomes with concurrent use of clopidogrel and proton‐pump inhibitors: a cohort study, Ann Intern Med, 152, 337, 10.7326/0003-4819-152-6-201003160-00003 Stockl, 2010, Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor, Arch Intern Med, 170, 704, 10.1001/archinternmed.2010.34 Sweeny, 2009, Mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents, Circulation, 120, S936 Torguson, 2009, Does proton pump inhibitor use following percutaneous coronary intervention with drug‐eluting stents impact clinical outcome?, Circulation, 120, S968 Ng, 2008, Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co‐therapy, Digestion, 77, 173, 10.1159/000141264 Harjai JK, Shenoy C, Orshaw P, Boura J, Rogers G Six‐Month Outcomes with or without Proton‐Pump Inhibitors after Successful PCI: Insights from the Guthrie PCI Registry. ACC 2010:A2903‐07. Charlot MG, Ahlehoff O, Jorgensen CH, Abildstrom SZ, Køber L, Hansen PR, Torp‐Pedersen C, Gislason G. Proton Pump Inhibitors are Associated with Cardiovascular Risk Independent of Clopidogrel Use in Patients with Myocardial Infarction: A Nationwide Propensity Score Matched Study. ACC 2010; A1100‐273. Oshima S, Noda K, Fukushima H, Nakamura S, Taniguchi I, Kugimiya F, Higa K, Nishijima T, Hanatani S. Pharmacodynamic Effects and Clinical Outcomes of Clopidogrel and Ticlopidine with or without a Proton‐pump Inhibitor. ACC 2010 Atlanta A:1021–110. Gaglia, 2010, Relation of proton pump inhibitor use after percutaneous coronary intervention with drug‐eluting stents to outcomes, Am J Cardiol, 105, 833, 10.1016/j.amjcard.2009.10.063 Hall, 2009, Cardiovascular risk associated with concurrent proton pump inhibitor and clopidogrel therapy: how much? how specific?, Circulation, 120, S422 Rossini, 2009, Prevalence, predictors, and long‐term prognosis of discontinuation of oral antiplatelet therapy after DES implantation, Eur Heart J, 30 Ching, 2009, Proton pump inhibitors increase major adverse cardiac events among post percutaneous coronary intervention patients on clopidogrel, Circulation, 120, S936 Shimomura H, Hokimoto S, Ogawa H, Investigators TK. Clinical outcomes following coronary stenting in Japanese patients with and without proton pump inhibitor. ACC 2010; A:1074–99. Ng, 2008, Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome, Am J Gastroenterol, 103, 865, 10.1111/j.1572-0241.2007.01715.x Kwok, 2010, Meta‐analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel, Aliment Pharmacol Ther, 31, 810 Hulot, 2010, Cardiovascular risk in clopidogrel‐treated patients according to cytochrome P450 2C19*2 loss‐of‐function allele or proton pump inhibitor coadministration: a systematic meta‐analysis, J Am Coll Cardiol, 56, 134, 10.1016/j.jacc.2009.12.071 Damman, 2009, Both in‐ and out‐hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH), Eur J Heart Fail, 11, 847, 10.1093/eurjhf/hfp108 Rasoul, 2009, Predictors of 30‐day and 1‐year mortality after primary percutaneous coronary intervention for ST‐elevation myocardial infarction, Coron Artery Dis, 20, 415, 10.1097/MCA.0b013e32832e5c4c Shaw, 2008, Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug‐eluting stents, Cardiovasc Revasc Med, 9, 218, 10.1016/j.carrev.2008.05.002 Sibbing, 2009, Platelet reactivity after clopidogrel treatment assessed with point‐of‐care analysis and early drug‐eluting stent thrombosis, J Am Coll Cardiol, 53, 849, 10.1016/j.jacc.2008.11.030 Marcucci, 2009, Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point‐of‐care assay: a 12‐month follow‐up, Circulation, 119, 237, 10.1161/CIRCULATIONAHA.108.812636 Lemesle, 2009, Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome, Am Heart J, 157, 375, 10.1016/j.ahj.2008.09.013 Angiolillo, 2007, Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease, J Am Coll Cardiol, 50, 1541, 10.1016/j.jacc.2007.05.049 Ang, 2008, Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel, J Am Coll Cardiol, 52, 1052, 10.1016/j.jacc.2008.05.054 Aggarwal, 2009, Incidence and predictors of stroke associated with percutaneous coronary intervention, Am J Cardiol, 104, 349, 10.1016/j.amjcard.2009.03.046 Salustri, 1999, Prediction of cardiac events after uncomplicated acute myocardial infarction by clinical variables and dobutamine stress test, J Am Coll Cardiol, 34, 435, 10.1016/S0735-1097(99)00232-6 Gilard, 2006, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x Siller‐Matula, 2007, Thienopyridines in cardiovascular disease: focus on clopidogrel resistance, Thromb Haemost, 97, 385, 10.1160/TH06-08-0420 Zanger, 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation, Anal Bioanal Chem, 392, 1093, 10.1007/s00216-008-2291-6 Khalique, 2009, Drug interaction between clopidogrel and proton pump inhibitors, Cardiol Rev, 17, 198, 10.1097/CRD.0b013e3181a857ba Vandenbroucke, 2004, Commentary: the HRT story: vindication of old epidemiological theory, Int J Epidemiol, 33, 456, 10.1093/ije/dyh121